01:30 PM EDT, 08/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target price to $58 from $45, 12.8x our FY 26 (Sep.) EPS estimate, a discount to HOLX's historical forward average due to softness in the Breast Health segment. We widen our FY 25 EPS estimate by $0.03 to $4.23 and trim FY 26's by $0.04 to $4.52. FQ3 EPS of $1.08 vs. $1.06, beat consensus by $0.03. Skeletal Health is recovering well, with sales up 64.7% Y/Y, reflecting the resolution of prior Horizon DXA stop-ship issues that had constrained performance for several quarters. The Diagnostics segment had light sales growth of 1.8% Y/Y, driven by market share gains in women's health testing and infectious disease diagnostics. However, Breast Health (the second largest segment) results were challenging, with sales down 5.1% Y/Y due to lower mammography capital equipment sales as expected. In addition, operating margin of 30.1% declined 110 bps Y/Y due to margin dilution from recent acquisitions. We expect soft demand in Breast Health to continue through year end.